机构:[1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China[2]Department of Rheumatology, the Second Affiliated Hospital of Nanchang University, Nanchang, China[3]Department of Rheumatology, the First Hospital of China Medical University, Shenyang,China[4]Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China[5]Department[6]Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[7]Department of Rheumatology, the First People’s Hospital of Yunnan Province, Kunming, China内科片风湿免疫科云南省第一人民医院[8]Department of Rheumatology, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China[9]Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, China[10]Department of Rheumatology, the First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China[11]Department of Rheumatology, the First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[12]Department of Rheumatology, the First Affiliated Hospital of Baotou Medical College, Baotou, China内蒙古科技大学包头医学院[13]National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China[14]State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China
This study was supported by the Chinese National Key Technology R&D
Program, Ministry of Science and Technology (2024YFC2510304, 2022YFC2504603),
CAMS Innovation Fund for Medical Sciences (CIFMS) (2023-I2M-2-005, 2023-I2M-C&T
B-035, 2021-I2M-1-005 ) and National High Level Hospital Clinical Research Funding
(2022-PUMCH-C-020, 2022-PUMCH-D-009, 2022-PUMCH-A-107), and State Key
Laboratory Special Fund 2060204.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
无
最新[2025]版:
大类|1 区医学
小类|1 区皮肤病学
第一作者:
第一作者机构:[1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China[14]State Key Laboratory of Common Mechanism Research for Major Diseases, Beijing, China
推荐引用方式(GB/T 7714):
Yu Chen,Wu Chanyuan,Jin Shangyi,et al.The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies[J].Journal Of The American Academy Of Dermatology.2025,doi:10.1016/j.jaad.2025.06.062.
APA:
Yu Chen,Wu Chanyuan,Jin Shangyi,Peng Liying,Duan Xinwang...&Wang Qian.(2025).The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies.Journal Of The American Academy Of Dermatology,,
MLA:
Yu Chen,et al."The Prospective Registry Of MyositIS (PROMIS): II. Temporal shifts in causes of death among patients with idiopathic inflammatory myopathies".Journal Of The American Academy Of Dermatology .(2025)